According to the National Academy of Clinical Biochemistry (NACB), the use of %fPSA is recommended to differentiate patients with a suspicion of prostate cancer from those with BPH, when total serum PSA levels are between 4–10 ng/mL [33]. Here, KLK3 is linked to benign prostatic hyperplasia.